RABIPUR®

Rabies vaccine (inactivated). Rabipur® is a vaccine for rabies with more than 35 years of worldwide clinical experience.¹ Help protect your travellers against rabies.

Key facts

Rabipur® is a vaccine for rabies with more than 35 years of worldwide clinical experience.¹
It is indicated for active immunisation against rabies in individuals of all ages.²
Conventional and rapid* primary immunisation regimens possible for immune protection when you need it.²
When administered according to the recommended immunisation schedule in clinical trials, almost all subjects achieved an adequate immune response.²
Rabipur® is generally well-tolerated; in clinical trials and in postmarketing surveillance, the most commonly reported adverse reactions were: headache, dizziness, rash, malaise, fatigue, asthenia, fever, injection site reactions - pain (30-85%) or induration (15-35%). Most injection site reactions were not severe and resolved within 24 to 48 hours.²

*Rapid regimen for adults aged 18-65 not able to complete the conventional regimen.²

How you should administer RABIPUR®²

View Prescribing Information Further information on SMPC Further information on PIL

Place an order

References

Giesen A, Gniel O, Malerczyk C. 2015. 30 years of rabies vaccination with Rabipur: a summary of clinical data and global experience. Expert Review of Vaccines, 14:3, 351-367, doi: 10.1586/14760584.2015.1011134
Valneva UK Limited – Rabipur® Summary of Product Characteristics. April 2021. Available online: medicines.org.uk (Last accessed March 2023).
WHO. Vaccinating against rabies to save lives. who.int. (Last accessed March 2023)

Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Valneva UK Ltd Medical Information department on Tel: 01506 446608 or via email: vaccinesafety@valneva.com